The decision by the National Institute for Health and Care Excellence (NICE) not to recommend Enhertu for NHS breast cancer treatment has left many patients and clinicians feeling disappointed and uncertain about their future care options. Enhertu, a promising new treatment co-developed by AstraZeneca and Daiichi Sankyo, was hoped to bring relief to those living with HER2-low metastatic breast cancer, a type of advanced disease that is notoriously difficult to treat.
Enhertu (trastuzumab deruxtecan) works by targeting and destroying HER2-positive cancer cells. While the initial clinical trials have shown positive results, NICE's preliminary assessment has raised concerns about the cost-effectiveness of this treatment in relation to its benefits. The independent appraisal committee also highlighted uncertainties around how well Enhertu works in the long term, particularly when compared to existing treatments available on the NHS.
This decision affects adults in England and Wales living with HER2-low metastatic breast cancer who have already received chemotherapy for their advanced disease. As it stands, this group will not be eligible for funding of Enhertu through the NHS. According to NICE's own guidelines, any new treatments must demonstrate significant benefits and value for money before being recommended for widespread use.
AstraZeneca and Daiichi Sankyo, along with patient advocacy groups and healthcare professionals, now have an opportunity to appeal this decision by submitting further evidence, clarifying data, or proposing alternative pricing models during the consultation period. This can sometimes lead to a reversal or modification of NICE's initial recommendations if new information comes to light.
Breast cancer remains one of the most common cancers in the UK, with around 55,000 people diagnosed each year (NHS Digital, 2020). While survival rates have improved significantly for early-stage disease, metastatic breast cancer continues to be a challenging area. The development and availability of new treatments like Enhertu are crucial for improving outcomes and offering hope to those living with advanced forms of the disease.
NICE's role is to ensure that NHS patients receive treatments that are clinically effective while representing good value for money for taxpayers. By carefully balancing innovation with affordability, NICE helps to drive forward improvements in healthcare without breaking the bank (NICE, 2022). The final decision on Enhertu will be announced after the consultation period has concluded.